Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal lead.

ABSTRACT:

Background

Kidney transplant recipients (KTR) with high-normal lead have a higher risk of graft failure (GF). Clinically, chelation therapy using meso-2,3-dimercaptosuccinic acid (DMSA) removes lead. Despite the proposal that chelation therapy can prevent GF through lead removal, evidence is lacking. To guide research efforts, we conducted an early economic evaluation, aiming to explore the economic feasibility of screening for and implementing chelation therapy with oral DMSA for high-normal plasma lead concentrations in KTR (i.e., the intervention) compared to standard of care.

Methods

A Markov model simulated the life course of 10,000 KTR in the Netherlands from a societal perspective. Transition probabilities were estimated using the data from TransplantLines Food and Nu

SUBMITTER: Hao J 

PROVIDER: S-EPMC11867398 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature